Alzheimer's Disease Circadian Rhythm and Sleep-Wake Cycle Therapy Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies targeting circadian rhythm dysregulation and sleep-wake cycle disruption in Alzheimer's disease. Circadian dysfunction is both an early biomarker and a pathogenic driver in AD — the suprachiasmatic nucleus (SCN) and peripheral clocks become dysregulated, accelerating neurodegeneration through impaired glymphatic clearance, altered microglial activation, and disrupted metabolic homeostasis. Restoring circadian alignment represents a novel therapeutic approach targeting a fundamental yet underexplored dimension of AD pathophysiology[@musiek2016][@lananna2020].

The main therapeutic targets in this space include:

• Melatonin pathway — MT1/MT2 receptor agonism to restore nocturnal sleep and antioxidant signaling
• Orexin system — OX1/OX2 receptor antagonism or agonism to normalize sleep-wake transitions
• BMAL1/CLOCK modulation — SIRT1 activation and REV-ERB agonism to reinforce clock gene expression
• Light entrainment — photobiomodulation and bright light therapy to strengthen zeitgeber input
• Glymphatic activation — sleep-dependent clearance enhancement

Key Companies

Neurim Pharmaceuticals (Melatonin Agonist)

Mechanism: Melatonin receptor agonist (piromelatine)

Clinical Stage: Phase 2/3 (AD)

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies targeting circadian rhythm dysregulation and sleep-wake cycle disruption in Alzheimer's disease. Circadian dysfunction is both an early biomarker and a pathogenic driver in AD — the suprachiasmatic nucleus (SCN) and peripheral clocks become dysregulated, accelerating neurodegeneration through impaired glymphatic clearance, altered microglial activation, and disrupted metabolic homeostasis. Restoring circadian alignment represents a novel therapeutic approach targeting a fundamental yet underexplored dimension of AD pathophysiology[@musiek2016][@lananna2020].

The main therapeutic targets in this space include:

• Melatonin pathway — MT1/MT2 receptor agonism to restore nocturnal sleep and antioxidant signaling
• Orexin system — OX1/OX2 receptor antagonism or agonism to normalize sleep-wake transitions
• BMAL1/CLOCK modulation — SIRT1 activation and REV-ERB agonism to reinforce clock gene expression
• Light entrainment — photobiomodulation and bright light therapy to strengthen zeitgeber input
• Glymphatic activation — sleep-dependent clearance enhancement

Key Companies

Neurim Pharmaceuticals (Melatonin Agonist)

Mechanism: Melatonin receptor agonist (piromelatine)

Clinical Stage: Phase 2/3 (AD)

Background: Neurim Pharmaceuticals is a specialty pharma company focused on circadian rhythm therapeutics. Piromelatine (TH-102) is a novel melatonin MT1/MT2 receptor agonist with additional serotonin 5-HT2C antagonist activity. It is being developed for AD patients with comorbid sleep disturbances and circadian dysregulation[@neurim2024].

Key Science:

• Melatonin levels decline sharply with age, and this decline is exaggerated in AD
• MT1/MT2 receptor activation promotes sleep initiation, reduces nocturnal agitation ("sundowning"), and exerts neuroprotective antioxidant effects
• Piromelatine's dual mechanism (melatonin agonism + mild 5-HT2C antagonism) addresses both sleep and mood symptoms common in AD
• Phase 2 trials showed improvement in sleep efficiency and cognitive outcomes in AD patients

Vielight Inc. (Photobiomodulation)

Mechanism: Near-infrared photobiomodulation (PBM) via intranasal and/or transcranial delivery

Clinical Stage: Phase 2 (AD/PD)

Background: Vielight develops non-invasive neurostimulation devices using photobiomodulation — low-level laser/LED light in the near-infrared spectrum (810 nm). Their Neuro Alpha device combines intranasal infrared light delivery to the suprachiasmatic nucleus region with transcranial stimulation. PBM is theorized to enhance mitochondrial function in neurons, improve SCN clock function, and reduce neuroinflammation[@vielight2024].

Key Science:

• Near-infrared light penetrates tissue to reach deep brain structures including the hypothalamus
• Photobiomodulation upregulates cytochrome c oxidase, enhancing ATP production in neurons
• PBM applied to the SCN region may strengthen circadian entrainment and improve sleep-wake consolidation
• Multiple pilot studies in AD/PD have shown improvements in sleep quality, circadian amplitude, and cognitive function
• Non-pharmacological approach avoids drug-drug interactions — relevant for polypharmacy in elderly AD patients

Axsome Therapeutics (Sigma-1 Agonist / Sleep Programs)

Mechanism: Sigma-1 receptor agonist (AXS-12 — reboxetine analog with sigma-1 agonism)

Clinical Stage: Phase 2 (AD agitation — AXS-060); AXS-12 in preclinical/early clinical

Background: While Axsome's primary AD focus is AXS-060 (sigma-1 agonist for agitation), they have explored sleep-wake modulation through sigma-1 receptor pathways. The sigma-1 receptor is a chaperone at the endoplasmic reticulum-mitochondria interface that modulates calcium signaling, neuroplasticity, and circadian gene expression. Sigma-1 agonism may indirectly reinforce clock gene expression and improve sleep quality in AD[@axsome2024].

Key Science:

• Sigma-1 receptors are highly expressed in SCN neurons and regulate circadian rhythms
• Sigma-1 agonism enhances neuronal resilience and modulates the sleep-wake cycle
• AXS-12 was being explored for narcolepsy and sleep disorders before shifting focus to AD agitation
• Their existing sigma-1 agonist platform (AXS-060) may provide circadian benefits in addition to agitation reduction

Eisai Co. (Lemborexant — Orexin Antagonist)

Mechanism: Dual orexin OX1/OX2 receptor antagonist (lemborexant)

Clinical Stage: Approved for insomnia (Dayvigo); Phase 2 trials in AD (SUNMOON trial)

Background: Eisai developed lemborexant (Dayvigo), a dual orexin receptor antagonist approved for insomnia disorder. In AD, Eisai is investigating whether orexin antagonism can improve sleep quality and potentially modulate AD pathology. The orexin system regulates wakefulness through hypothalamic neurons that project widely through the brain. In AD, orexin neurons may become dysregulated, contributing to fragmented sleep-wake cycles[@eisai2024][@eisai_lemp].

Key Science:

• Orexin (hypocretin) neurons in the lateral hypothalamus drive wakefulness and arousal
• Lemborexant blocks OX1 and OX2 receptors, reducing wake-promoting orexin signaling and facilitating sleep onset
• The SUNMOON trial (NCT05117086) evaluated lemborexant in AD patients with insomnia
• Improved sleep in AD patients may enhance glymphatic clearance of Aβ and tau overnight
• Sleep fragmentation correlates with higher amyloid burden — treating insomnia may modify disease trajectory

Takeda Pharmaceutical (Circadian Clock Modulators)

Mechanism: REV-ERB agonist / SIRT1 activator programs (discovery/early research)

Clinical Stage: Discovery

Background: Takeda has explored circadian clock modulators including REV-ERB agonists and SIRT1 activators as potential treatments for neurodegenerative diseases. The nuclear receptors REV-ERBα and REV-ERBβ are key components of the clock feedback loop — their agonism can reinforce BMAL1 expression and strengthen circadian amplitude. SIRT1, a NAD+-dependent deacetylase, regulates BMAL1 acetylation and links circadian rhythms to metabolic state[@takeda2024].

Key Science:

• REV-ERB agonists (e.g., SR9009, SR9011) have shown neuroprotective effects in models of neurodegeneration
• SIRT1 activation (via NAD+ boosters or direct agonists) enhances BMAL1 deacetylation and improves clock function
• Takeda's aging and neuroscience research programs include circadian clock enhancers as a strategic priority
• No clinical-stage programs publicly disclosed as of 2025, but the pipeline suggests ongoing discovery work

Signify Research / Light Therapy Companies

Mechanism: Bright light therapy / blue-enriched light exposure

Clinical Stage: Research / Clinical use (non-pharmacological)

Background: Multiple companies and academic medical centers offer bright light therapy devices for circadian entrainment in aging and neurodegeneration. While no single company dominates this space, it represents an important non-pharmacological approach. Philips (Somneo Sleepcare), Respi, and others have developed light therapy devices used in AD clinical settings to improve sleep-wake consolidation[@light2024].

Key Science:

• Bright light (10,000 lux) in the morning strengthens circadian entrainment via the retinohypothalamic tract
• AD patients often have reduced light exposure and weakened zeitgeber input
• Light therapy reduces sleep fragmentation, increases sleep efficiency, and improves circadian amplitude in AD
• Combination with melatonin in the evening further strengthens circadian alignment

Other Companies in Circadian/Sleep-AD Space

| Company | Mechanism | Stage | Notes |
|---------|-----------|-------|-------|
| Lonza | NAD+ precursors (SIRT1 activation) | Research | NMN and NR for circadian clock support |
| ChromaDex | SIRT1 activator (NR) | Research | Targets metabolic circadian coupling |
| Cyclerion | REV-ERB agonist | Preclinical | CYhip-01 for circadian reinforcement |
| Roaring 20s | SIRT1 modulators | Discovery | Novel sirtuin modulators |
| AbbVie | Orexin programs | Discovery | OX1/OX2 antagonists for AD sleep disorders |
| Roche | Circadian biology | Research | Broad clock gene research program |
| UCB Pharma | Melatonin pathway | Research | MT1/MT2 focused drug discovery |

Mechanism of Action

Circadian Dysfunction in AD

Therapeutic Interventions

| Target | Drug/Program | Company | Mechanism | Stage |
|--------|-------------|---------|-----------|-------|
| Melatonin MT1/MT2 | Piromelatine | Neurim | Agonist — restores nocturnal signaling | Phase 2/3 |
| Near-infrared PBM | Neuro Alpha | Vielight | SCN stimulation — strengthens zeitgeber | Phase 2 |
| Sigma-1 receptor | AXS-060 | Axsome | Agonist — clock gene support | Phase 2 |
| Orexin OX1/OX2 | Lemborexant | Eisai | Antagonist — sleep normalization | Phase 2 (AD) |
| REV-ERB | CYhip-01 | Cyclerion | Agonist — reinforces BMAL1 | Preclinical |
| SIRT1 | NR/NMN | ChromaDex/Lonza | Activator — metabolic circadian coupling | Research |
| Light | Bright light | Philips/Signify | Zeitgeber — strengthens SCN | Clinical use |
| Orexin OX1/OX2 | Various | AbbVie | Antagonists | Discovery |

Scientific Rationale

Melatonin and AD

Melatonin (N-acetyl-5-methoxytryptamine) is the primary hormone of darkness, secreted by the pineal gland during the biological night. In AD, melatonin levels decline dramatically — even before clinical symptoms appear — and this decline correlates with circadian rhythm disruption. Melatonin acts through two G-protein coupled receptors (MT1 and MT2) that are widely distributed in the SCN, hippocampus, and cortex. Beyond sleep promotion, melatonin exerts antioxidant, anti-amyloid, and anti-inflammatory effects in the brain. Melatonin therapy in AD has shown improvements in sleep quality, sundowning, and potentially cognitive outcomes[@cardinal2012][@lin2019].

Orexin and Sleep-Wake in AD

The orexin (hypocretin) system consists of hypothalamic neurons producing orexin-A and orexin-B peptides that signal through OX1 and OX2 receptors to promote wakefulness. In AD, orexin neuron function is disrupted, leading to sleep-wake fragmentation. Dual orexin receptor antagonists (DORAs) like lemborexant promote sleep by blocking orexin signaling, enabling patients to fall asleep and stay asleep more effectively. This is particularly relevant in AD patients with insomnia, where sleep fragmentation may accelerate amyloid clearance deficits[@sakurai2007].

SIRT1/BMAL1 Clock Modulation

SIRT1 (sirtuin 1) is a NAD+-dependent deacetylase that links cellular metabolism to circadian gene expression. SIRT1 deacetylates BMAL1 and PER2, modulating the clock transcriptional-translational feedback loop. SIRT1 activity follows a circadian rhythm and declines with aging — this decline may contribute to clock dysfunction in AD. SIRT1 activators (resveratrol, NAD+ boosters like NMN or NR) have shown benefit in AD models by restoring clock function and enhancing metabolic resilience[@lananna2020].

Light Therapy and Circadian Entrainment

Light is the primary zeitgeber (time-giver) that entrains the SCN to the 24-hour day. In AD patients, reduced visual acuity, limited outdoor exposure, and institutional settings lead to inadequate light input, weakening circadian entrainment. Bright light therapy (morning exposure to 10,000 lux white light) strengthens SCN function, improves sleep-wake consolidation, and reduces circadian rhythm disorders in AD. The combination of morning bright light and evening melatonin represents a non-pharmacological first-line approach[@van2022].

Competitive Landscape

The circadian/sleep therapeutic field for AD is emerging, with no approved disease-modifying treatments specifically targeting clock function in AD. Key differentiators:

| Approach | Advantages | Risks |
|----------|------------|-------|
| Melatonin agonists | Well-tolerated, addresses multiple pathways (sleep + neuroprotection) | Modest efficacy for sleep alone |
| Orexin antagonists | Direct sleep-wake normalization, approved for insomnia | May not address underlying clock dysfunction |
| Photobiomodulation | Non-pharmacological, no drug interactions | Device-based, limited reimbursement, variable delivery |
| SIRT1/REV-ERB | Targets core clock machinery, disease-modifying potential | Early stage, unclear translation |
| Light therapy | Safe, evidence-based, low cost | Compliance challenges, weak effect size |

Key Open Questions

Cross-Links

• [Circadian Dysfunction AD Pathway](/mechanisms/circadian-dysfunction-ad-pathway) — molecular mechanism linking clock disruption to AD
• [Circadian Rhythm Dysfunction AD](/mechanisms/circadian-rhythm-dysfunction-alzheimers) — broader clinical review
• [Melatonin Agonist Therapy](/therapeutics/melatonin-agonist-therapy-neurodegeneration) — detailed melatonin pharmacology
• [Orexin Receptor Modulators](/therapeutics/orexin-receptor-modulators) — orexin system in neurodegeneration
• [Circadian Rhythm Modulation Therapy](/therapeutics/circadian-rhythm-modulation) — therapeutic overview
• [Sleep-Circadian Dysfunction AD](/mechanisms/sleep-circadian-dysfunction-alzheimers) — sleep disruption in AD
• [Glymphatic-Circadian Axis](/therapeutics/glymphatic-circadian-axis-parkinsons) — sleep-dependent clearance mechanisms

References